| Patrick T Carroll, MD | |
|
1600 Eureka Rd, Roseville, CA 95661-3027 | |
| (916) 784-4000 | |
| Not Available |
| Full Name | Patrick T Carroll |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 35 Years |
| Location | 1600 Eureka Rd, Roseville, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114005857 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | G71844 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of California Davis Medical Center | Sacramento, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The Univ Of Ca | 3375456619 | 1346 |
News Archive
Hackensack Meridian Health Bayshore Medical Center Foundation is pleased to reveal that the new Emergency Care Center at Bayshore Medical Center in Holmdel, NJ, will be called the Dr. Robert H. Harris Emergency Care Center.
An international research consortium has confirmed that common genetic variants contribute to a person's risk of schizophrenia and bipolar disorder. The largest study of its kind provides new molecular evidence that 11 regions have strong association with these diseases, including six regions not previously observed. The researchers also found that many of these DNA variations contribute to both diseases. The findings, reported by the Psychiatric Genome-Wide Association Study Consortium (PGC) and published online in two papers in the journal Nature Genetics, represent significant advances in the understanding the causes of these severe and often debilitating disorders.
As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.
› Verified 8 days ago
| Entity Name | Regents Of The Univ Of Ca |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013906973 PECOS PAC ID: 3375456619 Enrollment ID: O20031111000892 |
News Archive
Hackensack Meridian Health Bayshore Medical Center Foundation is pleased to reveal that the new Emergency Care Center at Bayshore Medical Center in Holmdel, NJ, will be called the Dr. Robert H. Harris Emergency Care Center.
An international research consortium has confirmed that common genetic variants contribute to a person's risk of schizophrenia and bipolar disorder. The largest study of its kind provides new molecular evidence that 11 regions have strong association with these diseases, including six regions not previously observed. The researchers also found that many of these DNA variations contribute to both diseases. The findings, reported by the Psychiatric Genome-Wide Association Study Consortium (PGC) and published online in two papers in the journal Nature Genetics, represent significant advances in the understanding the causes of these severe and often debilitating disorders.
As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patrick T Carroll, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3429 Ph: (510) 625-6262 | Patrick T Carroll, MD 1600 Eureka Rd, Roseville, CA 95661-3027 Ph: (916) 784-4000 |
News Archive
Hackensack Meridian Health Bayshore Medical Center Foundation is pleased to reveal that the new Emergency Care Center at Bayshore Medical Center in Holmdel, NJ, will be called the Dr. Robert H. Harris Emergency Care Center.
An international research consortium has confirmed that common genetic variants contribute to a person's risk of schizophrenia and bipolar disorder. The largest study of its kind provides new molecular evidence that 11 regions have strong association with these diseases, including six regions not previously observed. The researchers also found that many of these DNA variations contribute to both diseases. The findings, reported by the Psychiatric Genome-Wide Association Study Consortium (PGC) and published online in two papers in the journal Nature Genetics, represent significant advances in the understanding the causes of these severe and often debilitating disorders.
As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.
Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.
› Verified 8 days ago
Mr. Jaspreet Singh Dhanjal, D.O. Rheumatology Medicare: Medicare Enrolled Practice Location: 2235 Douglas Blvd Ste 510, Roseville, CA 95661 Phone: 916-446-4449 Fax: 916-446-4370 | |
James H. Heykes, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 1600 Eureka Rd, Roseville, CA 95661 Phone: 916-784-4000 | |
Dr. Lakhvir Kaur, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2 Medical Plaza Dr Ste 200, Roseville, CA 95661 Phone: 916-797-4715 | |
Dr. John T Bakos, M.D., PHD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 729 Sunrise Ave, Suite 610, Roseville, CA 95661 Phone: 916-347-7001 Fax: 916-304-1633 | |
Uma H Gowda, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 8 Medical Plaza Dr Ste 300, Roseville, CA 95661 Phone: 916-782-5106 Fax: 916-878-4941 | |
Peter A. Javaheri, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1600 Eureka Rd, Roseville, CA 95661 Phone: 916-784-4000 | |
Rani Reddy Vatti, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 1600 Eureka Rd, Roseville, CA 95661 Phone: 916-784-4000 |